Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Myasthenia gravis (MG) disrupts signals between your nerves and voluntary muscles, especially the ones that control your: Eyes or eyelids Face, jaw, and mouth Neck and throat area Arms ...

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially ...

How Is Myasthenia Gravis Diagnosed? During a physical exam for myasthenia gravis, your health care provider may look for signs such as a droopy eyelid, difficulty holding your arms out at shoulder ...

Winnacunnet High School senior Joe Labrecque has transformed his battle with a rare chronic illness into a mission to help others.

Myasthenia gravis is an autoimmune disease caused by neuromuscular junction transmission disorders. It is characterized by fluctuating muscle weakness and fatigue in symptoms, long treatment ...

Ocular myasthenia gravis is an autoimmune condition affecting the muscles surrounding and involving the eyes. Symptoms can include double vision, droopy eyelids, and more. Ocular myasthenia gravis ...

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia ...

Highlights in myasthenia gravis (MG) from the American Academy of Neurology 2025 Annual Meeting include new therapy trials and practice reviews, as discussed by Dr Nicholas Silvestri of the ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis. The Food and Drug Administration (FDA) has approved Imaavy ...

Myasthenia gravis is an autoimmune disease caused by neuromuscular junction transmission disorders. It is characterized by fluctuating muscle weakness and fatigue in symptoms, long treatment cycles ...